Ultra Market Research | Europe EGFR and HER2 Targeted NSCLC Market
Europe EGFR and HER2 Targeted NSCLC Market
Report ID : 863
Category : Europe,Healthcare-Companies
No Of Pages : 138
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) targeted therapies have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC) in Europe. These therapies aim to inhibit abnormal cell signaling pathways that lead to uncontrolled cell proliferation, improving survival rates and patient outcomes. The market for EGFR and HER2-targeted NSCLC in Europe is characterized by growing adoption of precision medicine, increased investment in clinical trials, and an expanding pipeline of innovative drugs. Key trends include the integration of biomarker testing and advancements in companion diagnostics, which are helping to personalize and optimize treatment protocols.
Segmentation
Treatment Types
Targeted Therapies
Tyrosine Kinase Inhibitors (TKIs)
Monoclonal Antibodies
Others
Chemotherapy Combinations
Immunotherapy Combinations
Others
Diagnostic Methods
Biopsy-Based Diagnostics
Tissue Biopsy
Liquid Biopsy
Others
Imaging Techniques
Molecular Testing
PCR
Next-Generation Sequencing (NGS)
Others
End-Users
Hospitals
Cancer Treatment Centers
Diagnostic Laboratories
Academic and Research Institutions
Others
List of Market Players
AstraZeneca (United Kingdom)
Roche (Switzerland)
Novartis (Switzerland)
Pfizer (United States)
Amgen (United States)
Merck KGaA (Germany)
Boehringer Ingelheim (Germany)
Eli Lilly and Company (United States)
Sanofi (France)
Takeda Pharmaceutical (Japan)
Bristol Myers Squibb (United States)
Janssen Pharmaceuticals (Belgium)
Bayer AG (Germany)
Clovis Oncology (United States)
BioNTech (Germany)
Drivers
The Europe EGFR & HER2 targeted NSCLC market is driven by the increasing prevalence of lung cancer and advancements in genetic profiling technologies. The adoption of targeted therapies is rising as they provide higher efficacy with fewer side effects compared to traditional chemotherapy. Supportive government initiatives and funding for cancer research are bolstering market growth. Additionally, the growing acceptance of personalized medicine, fueled by advancements in molecular diagnostics, enhances the demand for EGFR and HER2-targeted treatments. The region's strong healthcare infrastructure facilitates the early adoption of innovative therapies.
Restraints
High treatment costs remain a significant barrier to market growth. Targeted therapies are expensive, making them inaccessible to some patient populations, particularly in underfunded healthcare systems. The development of EGFR and HER2-targeted drugs involves complex research and clinical trials, which can delay approvals and market entry. Furthermore, resistance to EGFR and HER2 inhibitors, as seen in some patients, necessitates continuous innovation, which can be resource-intensive. Regulatory hurdles and reimbursement challenges in different European countries further impede market expansion.
Opportunities
The rising investment in R&D by pharmaceutical companies creates significant opportunities for market growth. Expansion in emerging European markets, where cancer diagnostic and treatment infrastructure is developing, provides untapped potential. Collaborations between pharmaceutical firms and diagnostic companies to develop companion diagnostics can accelerate the adoption of EGFR and HER2 therapies. Additionally, advancements in liquid biopsy and NGS technologies offer opportunities for early detection and precision treatment, further driving the market.
Trends
A prominent trend is the integration of artificial intelligence and machine learning in biomarker identification and drug development processes. Companion diagnostic tools are becoming increasingly sophisticated, enabling real-time monitoring of treatment efficacy. The rise of combination therapies, which pair EGFR or HER2 inhibitors with immunotherapies, reflects a growing interest in enhancing therapeutic outcomes. Another trend is the use of real-world evidence and patient-centric trials to fast-track regulatory approvals for targeted therapies in Europe.
Approved Products
Osimertinib (Tagrisso) by AstraZeneca
Afatinib (Gilotrif) by Boehringer Ingelheim
Dacomitinib (Vizimpro) by Pfizer
Erlotinib (Tarceva) by Roche
Trastuzumab deruxtecan (Enhertu) by AstraZeneca/Daiichi Sankyo
Pipeline/Registered/Pre-Registered Products
Amivantamab (Janssen Pharmaceuticals)
Poziotinib (Spectrum Pharmaceuticals)
Patritumab deruxtecan (Daiichi Sankyo)
BI 4020 (Boehringer Ingelheim)
Mobocertinib (Takeda Pharmaceutical)
Key Target Audience
Pharmaceutical Companies
Biotech Firms
Cancer Research Institutes
Healthcare Providers
Regulatory Agencies
Patients and Caregivers
FAQs
These therapies target specific genetic mutations or protein expressions in cancer cells, aiming to inhibit tumor growth and spread.
Key drivers include the prevalence of lung cancer, advancements in diagnostics, and the demand for precision medicine.
High costs, drug resistance, and complex regulatory pathways are the primary challenges.
Germany, France, and the United Kingdom are key contributors due to robust healthcare systems and high adoption of innovative therapies.
Yes, products like Amivantamab and Poziotinib are in advanced stages of development and show significant promise.
Introduction
Overview of EGFR & HER2 Targeted NSCLC
Applications in Precision Medicine
Recent Trends in the Europe Market
Market Segmentation
By Treatment Types
Targeted Therapies
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Chemotherapy Combinations
Immunotherapy Combinations
By Diagnostic Methods
Biopsy-Based Diagnostics
Tissue Biopsy
Liquid Biopsy
Imaging Techniques
Molecular Testing
PCR
Next-Generation Sequencing (NGS)
By End-Users
Hospitals
Cancer Treatment Centers
Diagnostic Laboratories
Key Market Players
List of Major Companies with Headquarters
AstraZeneca (United Kingdom)
Roche (Switzerland)
Novartis (Switzerland)
Pfizer (United States)
Amgen (United States)
Merck KGaA (Germany)
Boehringer Ingelheim (Germany)
Eli Lilly and Company (United States)
Sanofi (France)
Takeda Pharmaceutical (Japan)
Bristol Myers Squibb (United States)
Janssen Pharmaceuticals (Belgium)
Bayer AG (Germany)
Clovis Oncology (United States)
BioNTech (Germany)
Market Drivers
Rising Prevalence of NSCLC
Advancements in Precision Diagnostics
Supportive Government Initiatives
Market Restraints
High Treatment Costs
Resistance to Targeted Therapies
Regulatory and Reimbursement Challenges
Market Opportunities
Expansion in Emerging European Markets
Collaborations for Companion Diagnostics
Advancements in Liquid Biopsy Technologies
Market Trends
Integration of AI in Drug Development
Rise of Combination Therapies
Real-World Evidence in Regulatory Approvals
Approved Products
EGFR and HER2-Targeted Drugs Approved in Europe
Pipeline, Registered, and Pre-Registered Products
Prominent Drugs in Development
Key Target Audience
Pharmaceutical and Biotech Companies
Research Institutions
Healthcare Providers
Frequently Asked Questions (FAQs)
Key Market Insights
Challenges and Opportunities
List of Tables
Table 1: Overview of EGFR & HER2 Targeted NSCLC in Europe
Table 2: Market Segmentation by Treatment Types
Table 3: Market Segmentation by Diagnostic Methods
Table 4: Market Segmentation by End-Users
Table 5: List of Key Market Players and Headquarters
Table 6: Drivers Impacting the Europe EGFR & HER2 Targeted NSCLC Market
Table 7: Restraints and Challenges in the Market
Table 8: Opportunities for Growth in Emerging Markets
Table 9: Approved Products for EGFR & HER2 Targeted NSCLC in Europe
Table 10: Pipeline, Registered, and Pre-Registered Products
Table 11: Key Target Audience for Market Insights
Table 12: FAQs on the Europe EGFR & HER2 Targeted NSCLC Market
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach. 2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Europe EGFR & HER2 Targeted NSCLC Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of Europe EGFR & HER2 Targeted NSCLC Market for the past year and forecasts for the next six years. Europe EGFR & HER2 Targeted NSCLC Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Europe EGFR & HER2 Targeted NSCLC Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Skincare Treatment from different application industries in different regions.
